POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
POLD1
POLE
Middle East
colorectal cancers
variant
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
23
01
2020
revised:
26
05
2020
accepted:
28
05
2020
pubmed:
23
6
2020
medline:
11
5
2021
entrez:
23
6
2020
Statut:
ppublish
Résumé
Colorectal cancer (CRC) is a major contributor to morbidity and mortality related to cancer. Only ~5% of all CRCs occur as a result of pathogenic variants in well-defined CRC predisposing genes. The frequency and effect of exonuclease domain pathogenic variants of POLE and POLD1 genes in Middle Eastern CRCs is still unknown. Targeted capture sequencing and Sanger sequencing technologies were employed to investigate the germline exonuclease domain pathogenic variants of POLE and POLD1 in Middle Eastern CRCs. Immunohistochemical analysis of POLE and POLD1 was performed to look for associations between protein expression and clinico-pathological characteristics. Five damaging or possibly damaging variants (0.44%) were detected in 1,135 CRC cases, four in POLE gene (0.35%, 4/1,135) and one (0.1%, 1/1,135) in POLD1 gene. Furthermore, low POLE protein expression was identified in 38.9% (417/1071) cases and a significant association with lymph node involvement (p = .0184) and grade 3 tumors (p = .0139) was observed. Whereas, low POLD1 expression was observed in 51.9% (555/1069) of cases and was significantly associated with adenocarcinoma histology (p = .0164), larger tumor size (T3 and T4 tumors; p = .0012), and stage III tumors (p = .0341). POLE and POLD1 exonuclease domain pathogenic variants frequency in CRC cases was very low and these exonuclease domain pathogenic variants might be rare causative events of CRC in the Middle East. POLE and POLD1 can be included in multi-gene panels to screen CRC patients.
Sections du résumé
BACKGROUND
Colorectal cancer (CRC) is a major contributor to morbidity and mortality related to cancer. Only ~5% of all CRCs occur as a result of pathogenic variants in well-defined CRC predisposing genes. The frequency and effect of exonuclease domain pathogenic variants of POLE and POLD1 genes in Middle Eastern CRCs is still unknown.
METHODS
Targeted capture sequencing and Sanger sequencing technologies were employed to investigate the germline exonuclease domain pathogenic variants of POLE and POLD1 in Middle Eastern CRCs. Immunohistochemical analysis of POLE and POLD1 was performed to look for associations between protein expression and clinico-pathological characteristics.
RESULTS
Five damaging or possibly damaging variants (0.44%) were detected in 1,135 CRC cases, four in POLE gene (0.35%, 4/1,135) and one (0.1%, 1/1,135) in POLD1 gene. Furthermore, low POLE protein expression was identified in 38.9% (417/1071) cases and a significant association with lymph node involvement (p = .0184) and grade 3 tumors (p = .0139) was observed. Whereas, low POLD1 expression was observed in 51.9% (555/1069) of cases and was significantly associated with adenocarcinoma histology (p = .0164), larger tumor size (T3 and T4 tumors; p = .0012), and stage III tumors (p = .0341).
CONCLUSION
POLE and POLD1 exonuclease domain pathogenic variants frequency in CRC cases was very low and these exonuclease domain pathogenic variants might be rare causative events of CRC in the Middle East. POLE and POLD1 can be included in multi-gene panels to screen CRC patients.
Identifiants
pubmed: 32567205
doi: 10.1002/mgg3.1368
pmc: PMC7434734
doi:
Substances chimiques
Poly-ADP-Ribose Binding Proteins
0
POLD1 protein, human
EC 2.7.7.-
DNA Polymerase II
EC 2.7.7.7
DNA Polymerase III
EC 2.7.7.7
POLE protein, human
EC 2.7.7.7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1368Informations de copyright
© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Références
Nat Genet. 2013 Feb;45(2):136-44
pubmed: 23263490
Oncotarget. 2019 Mar 22;10(24):2384-2396
pubmed: 31040929
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nat Genet. 2015 Jun;47(6):668-71
pubmed: 25938944
Gastroenterology. 2003 May;124(6):1574-94
pubmed: 12761718
Genet Med. 2016 Apr;18(4):325-32
pubmed: 26133394
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Genet Med. 2018 Oct;20(10):1299
pubmed: 29388942
Hum Mol Genet. 2010 Dec 1;19(23):4654-62
pubmed: 20843829
Nat Genet. 2002 Feb;30(2):227-32
pubmed: 11818965
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Cell. 2017 Nov 16;171(5):1042-1056.e10
pubmed: 29056344
J Clin Endocrinol Metab. 2008 Feb;93(2):611-8
pubmed: 18000091
Gastroenterology. 2010 Jun;138(6):2044-58
pubmed: 20420945
J Clin Oncol. 2015 Feb 10;33(5):426-32
pubmed: 25559809
Hum Mol Genet. 1998 Nov;7(12):1907-12
pubmed: 9811934
Nat Protoc. 2016 Jan;11(1):1-9
pubmed: 26633127
Mol Genet Genomic Med. 2020 Aug;8(8):e1368
pubmed: 32567205
J Cancer Educ. 2014 Dec;29(4):772-80
pubmed: 24715252
J Natl Compr Canc Netw. 2017 Feb;15(2):142-147
pubmed: 28188185
Oncogene. 1999 Aug 12;18(32):4643-6
pubmed: 10467410
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Mol Cell. 2008 Apr 25;30(2):137-44
pubmed: 18439893
Int J Oncol. 2016 Nov;49(5):2088-2104
pubmed: 27826616
Eur J Hum Genet. 2015 Aug;23(8):1080-4
pubmed: 25370038
Crit Rev Oncol Hematol. 2017 May;113:242-248
pubmed: 28427513
Cancer. 2015 Jun 1;121(11):1762-71
pubmed: 25712738
J Pathol. 2007 Oct;213(2):190-9
pubmed: 17703498
Cancer Treat Rev. 2019 Jun;76:22-32
pubmed: 31079031
N Engl J Med. 2000 Jul 13;343(2):78-85
pubmed: 10891514
Nat Commun. 2018 May 1;9(1):1746
pubmed: 29717118
Int J Cancer. 2015 Jul 15;137(2):320-31
pubmed: 25529843
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Gastroenterology. 2014 Feb;146(2):520-9
pubmed: 24512911
Cancer Cell Int. 2019 Dec 11;19:334
pubmed: 31866764
Hum Genet. 2017 Nov;136(11-12):1431-1444
pubmed: 28975465
Science. 2007 Jul 6;317(5834):127-30
pubmed: 17615360
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894
pubmed: 30371827
Hum Mol Genet. 2014 Jul 1;23(13):3506-12
pubmed: 24501277
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Nucleic Acids Res. 2011 Sep 1;39(17):e118
pubmed: 21727090
Nat Methods. 2014 Apr;11(4):361-2
pubmed: 24681721
Palliat Support Care. 2013 Feb;11(1):69-78
pubmed: 23171758
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593